Cargando…

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations

Acute exacerbations of COPD (AECOPD) are major clinical events. They are associated with a more rapid decline in lung function, poorer quality of life scores, and an increased risk of dying. Exacerbations that require hospitalization have particular significance. Approximately 40% of the AECOPD pati...

Descripción completa

Detalles Bibliográficos
Autor principal: Field, Stephen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212861/
https://www.ncbi.nlm.nih.gov/pubmed/22084617
http://dx.doi.org/10.4137/CCRPM.S7049